Overview
Protein-losing nephropathy involves excessive loss of protein into the urine, often due to glomerular damage, which can be exacerbated by factors such as aldosterone activation in diabetic conditions 1.Diagnosis
Assess proteinuria levels (albuminuria) using urine albumin-to-creatinine ratio (UACR) 1.
Evaluate renal function with serum creatinine and estimated glomerular filtration rate (eGFR) 1.
Consider renal biopsy for definitive diagnosis and grading of glomerular damage when clinical suspicion is high 1.Management
First-line treatments:
- Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to reduce proteinuria and protect renal function 1.
Adjunctive treatments:
- Mineralocorticoid receptor (MR) antagonists in selected patients, particularly those with diabetes, to further reduce albuminuria 1.Special Populations
Pregnancy: Focus antenatal care on identifying women at higher risk of proteinuric hypertension to mitigate maternal and perinatal mortality risks 2.Key Recommendations
Use ACE inhibitors or ARBs as first-line therapy to manage proteinuria and protect renal function in protein-losing nephropathy (Evidence: Strong 1).
Consider MR antagonism in patients with diabetes and significant proteinuria to enhance proteinuria reduction (Evidence: Moderate 1).
Prioritize risk stratification and targeted screening for proteinuric hypertension in pregnant women to improve outcomes (Evidence: Moderate 2).References
1 Nagase M, Fujita T. Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the aldosterone/mineralocorticoid receptor system. Current diabetes reviews 2011. link
2 Hall M, Campbell D. Cost-effectiveness of present programs for detection of asymptomatic hypertension in relation to the severity of hypertension and proteinuric hypertension. International journal of technology assessment in health care 1992. link